Global Legal Chronicle | OncoSec Medical’s $42 Million Shares Offering

Alston & Bird client OncoSec Medical Incorporated, a late-stage biotechnology company, has closed a public offering of common stock that raised approximately $42 million.

Brett Jaffe, Joe Tully, Matt Mamak, Dennis Garris, Dave Brown, Mark McElreath, James Sullivan, Gerard Catalanello, Jim Vincequerra, Bryan Skelton, and Gidon Caine are noted for successfully representing OncoSec Medical Inc. in a putative shareholder class action.

Alston & Bird client Nuvectis Pharma Inc., an oncology-focused biopharmaceutical company based in Fort Lee, NJ, has announced the closing of its initial public offering (IPO) of 3.2 million shares of common stock at a price of $5 per share, for gross proceeds of $16 million before deducting underwriting discounts and offering expenses.  All shares of common stock were offered by Nuvectis.

Matt Mamak, Justin Howard, Mark McElreath, Robyn Downing, Natalie Clayton, Maddy Byrd, Mike Stevens, and Brendan Caroll are noted for representing Stemline Therapeutics in its $677 million acquisition by Menarini Group.

Alston & Bird scored a decisive victory in Nevada state court last week by securing the dismissal with prejudice of a putative shareholder class action asserted against client OncoSec Medical Incorporated and its board of directors.